Glen Eagle Advisors, LLC Vertex Pharmaceuticals Inc Transaction History
Glen Eagle Advisors, LLC
- $593 Billion
- Q3 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 19 shares of VRTX stock, worth $8,557. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19
Previous 15
26.67%
Holding current value
$8,557
Previous $7.03 Million
25.69%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding VRTX
# of Institutions
1,723Shares Held
222MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$12.1 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.4 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.6 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.32 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.05 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $116B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...